Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib + bevacizumab after osimertinib for EGFR-mutant lung cancer
jRCTs031190077Phase 2Completed
- Start
- Dec 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib and bevacizumab in non-small cell lung cancer (NSCLC). Primary endpoint: Objective response rate. Started Dec 2019; status: completed.
02
Drugs
afatinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031190077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190077.